Mraz Amerine & Associates Inc. purchased a new stake in Sanofi (NYSE:SNY) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 4,095 shares of the company’s stock, valued at approximately $204,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Moors & Cabot Inc. lifted its stake in shares of Sanofi by 0.7% during the second quarter. Moors & Cabot Inc. now owns 6,494 shares of the company’s stock valued at $311,000 after buying an additional 43 shares during the period. Rehmann Capital Advisory Group lifted its stake in shares of Sanofi by 0.7% during the second quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock valued at $347,000 after buying an additional 47 shares during the period. Strategic Global Advisors LLC lifted its stake in shares of Sanofi by 0.6% during the second quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock valued at $414,000 after buying an additional 54 shares during the period. First City Capital Management Inc. lifted its stake in shares of Sanofi by 0.3% during the second quarter. First City Capital Management Inc. now owns 38,389 shares of the company’s stock valued at $1,839,000 after buying an additional 100 shares during the period. Finally, Clean Yield Group lifted its stake in shares of Sanofi by 0.3% during the second quarter. Clean Yield Group now owns 40,107 shares of the company’s stock valued at $1,932,000 after buying an additional 115 shares during the period. 9.36% of the stock is currently owned by institutional investors.

SNY has been the topic of several recent analyst reports. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. BidaskClub downgraded shares of Sanofi from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Cowen and Company reaffirmed a “market perform” rating and set a $52.00 price target (up previously from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. Finally, Argus reaffirmed a “buy” rating and set a $55.00 price target on shares of Sanofi in a research report on Friday, September 1st. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. Sanofi presently has an average rating of “Hold” and an average price target of $53.50.

Shares of Sanofi (NYSE:SNY) traded down $0.44 during mid-day trading on Monday, reaching $44.55. 225,425 shares of the company traded hands, compared to its average volume of 1,450,000. Sanofi has a 1 year low of $38.45 and a 1 year high of $50.65. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $112,930.00, a price-to-earnings ratio of 14.20, a price-to-earnings-growth ratio of 2.48 and a beta of 0.88.

ILLEGAL ACTIVITY WARNING: “4,095 Shares in Sanofi (SNY) Acquired by Mraz Amerine & Associates Inc.” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/4095-shares-in-sanofi-sny-acquired-by-mraz-amerine-associates-inc/1700167.html.

In other Sanofi news, major shareholder Sanofi acquired 60,595 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The stock was bought at an average price of $478.98 per share, with a total value of $29,023,793.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.00% of the company’s stock.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.